Submitted for Publication: September 12, 2012; final revision received January 31, 2013; accepted February 19, 2013.
Published Online: September 25, 2013. doi:10.1001/jamapsychiatry.2013.2048.
Study concept and design: Ludvigsson, Hultman.
Analysis and interpretation of data: All authors.
Drafting of the manuscript: Ludvigsson.
Critical revision of the manuscript for important intellectual content: All authors.
Conflict of Interest Disclosures: Dr Murray received grant support from Alba Therapeutics (>$50 000), served on the advisory board for Alvine Pharmaceuticals Inc (<$10 000) and Nexpep (<$10 000), and worked as a consultant (none >US $10 000) for Ironwood Inc, Flamentera, Actogenix, Ferring Research Institute Inc, Bayer Healthcare Pharmaceuticals, Vysera Biomedical, 2G Pharma, Inc, ImmunosanT, Inc, and Shire US, Inc. Dr Reichenberg received speaker honoraria from AstraZeneca.
Funding/Support: This study was supported by Orebro University Hospital, Karolinska Institutet, the Swedish Society of Medicine, grant 522-2A09-195 from the Swedish Research Council–Medicine, the Swedish Celiac Society, the Fulbright Commission (Dr Ludvigsson), grant 2011-4659 from The Swedish Research Council (Dr Hultman), and grants DK071003 and DK057892 from the National Institutes of Health (Dr Murray).
Role of the Sponsor: None of the funders had a role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Correction: This article was corrected online September 25, 2013, for duplicate entry of Author Contributions subheading.